Abnormal Platelet Aggregation Studies
Acquired causes of platelet dysfunction:
Ingestion of aspirin or aspirin-like compounds or NSAIDs
Impaired renal function
Exposure to cardiopulmonary bypass
Presence of a paraprotein
Congenital causes of platelet dysfunction:
Storage pool disease
Disorders of thromboxane production or action
Suggested Additional Lab Testing
Platelet aggregation studies with characteristic response patterns for the different agonists help identify Glanzmann thrombasthenia, Bernard-Soulier disease, aspirin ingestion, and defects in thromboxane production or action.
Plasma or serum BUN and creatinine and urinalysis to assess renal function should be ordered.
If aspirin ingestion is suspected but denied by patient, measurement of salicylates (metabolites of aspirin) may prove useful.
Bone marrow biopsy may be useful if myeloproliferative disease is suspected.
Serum protein electrophoresis can reveal a paraprotein. To identify platelet granule storage pool disease, assays for the granular contents of platelets can be performed, but these are complex, costly, and rarely performed.
Copyright © 2017, 2013 Decision Support in Medicine, LLC. All rights reserved.
No sponsor or advertiser has participated in, approved or paid for the content provided by Decision Support in Medicine LLC. The Licensed Content is the property of and copyrighted by DSM.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- CAR-T Trial for Triple-Negative Breast Cancer Under Way
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Phase 3 GEICAM/CIBOMA Results: Adjuvant Capecitabine in Triple-Negative Breast Cancer
- Rivaroxaban Reduced VTE and VTE-Related Death in Patients With Cancer: Results of the CASSINI Study
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Risk Score Identifies Adjuvant Chemotherapy Toxicity Risk in Elderly Patients With Breast Cancer
- Despite Breast-Conserving Surgery Eligibility, Nearly 50% of Women Chose Mastectomy
- Lisinopril and Carvedilol May Reduce Cardiotoxicity During Adjuvant Trastuzumab Treatment
- Immune Marker Identified as Prognostic in Triple-Negative Breast Cancer
- Rates of Adverse Events Similar Regardless of IMRT Boost Type